Jazz Pharmaceuticals (JAZZ) Stock Price, Quote, News & History | Benzinga

SPY778.14+0.01%QQQ741.92−0.55%BTC/USD83,905.82+2.65%DIA521.50+0.69%GLD384.05+0.50%TLT78.47+0.54%

Jazz Pharmaceuticals PLC (JAZZ) Stock Price, Quote, News & History

JAZZNASDAQ

Trade with Public

Trade with Public

$216.75

-1.67-0.76%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$216.75

Volume / Avg.

- / 863.97K

Day Range

- - -

52 Wk Range

128.80 - 266.38

Market Cap

$13.60B

P/E Ratio

14.84

Dividend Yield

-

Exchange

NASDAQ

RSI

25

Short Interest

10.05%

Days to Cover

6.48

Recent Jazz Pharmaceuticals PLC News

Jim Cramer Gives Green Light To This Health Care Stock

Cramer warns against Apple Hospitality if rates hit 6%, prefers Vylor over Corteva, backs Jazz, and notes SpaceX may bid for EchoStar.

Avi Kapoor

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development

Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.

Radhika Anilkumar Nadig

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.

Avi Kapoor

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut $MSTR target, Barclays raised $MDB target, UBS raised $SMTC target.

Avi Kapoor

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.66B

Investing Cash Flow (TTM)

-221.91M

Financing Cash Flow (TTM)

-1.01B

Free Cash Flow (TTM)

1.31B

Capital Expenditure (TTM)

-349.95M

Net Change in Cash (TTM)

430.68M

Analyst Trends and Forecast

1

Jun

6

Jul

14

Aug

4

Sep

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$16.39B

PE Ratio (TTM)

14.84

PE Ratio (FWD)

9.80

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.03

PB Ratio (TTM)

2.93

Earnings Yield % (TTM)

6.74%

Earnings Yield % (FWD)

10.20%

EV / EBITDA (TTM)

10.07

Price / EBITDA (TTM)

8.63

Price / Free Cash Flow (TTM)

10.64

Book Value / Share

$73.97

Company Debt

Total Debt

$4.35B

LT Debt

$3.34B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.03B

Total Cash

$1.62B

Debt to Equity

0.92

Issuance of Debt (TTM)

-$1.03B

Repayment of Debt (TTM)

-$1.03B